VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
As of Wednesday, November 18, Regencell Bioscience Holdings Limited’s RGC share price has surged by
7.25%, which has investors questioning if this is right time to sell.
As of Tuesday, November 17, Regencell Bioscience Holdings Limited’s RGC share price has dipped by
5.08%, which has investors questioning if this is right time to buy.
As of Monday, November 16, Regencell Bioscience Holdings Limited’s RGC share price has dipped by
5.67%, which has investors questioning if this is right time to buy.
As of Friday, November 13, Regencell Bioscience Holdings Limited’s RGC share price has dipped by
5.37%, which has investors questioning if this is right time to buy.
As of Thursday, November 12, Regencell Bioscience Holdings Limited’s RGC share price has dipped by
5.55%, which has investors questioning if this is right time to buy.
Michael Rose
Financial Summary
Share Statistics
RGC
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$2,072.8
$421.5
56%
Shares Out (Mil)
494.7
46.9
88%
Institutional Ownership
0.3%
82.0%
1%
Float (Mil)
55.1
49.2
48%
Beta
1.17
0.68
68%
Avg Daily Volume (000s)
117
347
38%
Price Change (52-week)
(67.5%)
49.3%
14%
Growth
RGC
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
6.4%
na
Net Income (5yr)
(55.2%)
(1.3%)
6%
EPS (5yr)
(43.1%)
15.1%
5
Dividends (5yr)
na
0.0%
na
Cash Flow (5yr)
na
(15.0%)
na
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
na
na
na
Month Ago EPS
na
na
na
# Rev Up
na
na
na
# Rev Down
na
na
na
Three Months Ago EPS
na
na
na
Year/Year Chg
na
na
na
Financials
RGC
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$275
na
Net Income (TTM) (Mil)
($12)
($11)
27%
EPS (TTM)
($0.024)
($0.700)
37%
Operating Cash Flow (TTM) (Mil)
($8)
($7)
22%
Net Cash Flow (TTM) (Mil)
na
$1
na
Long-Term Debt (Q1) (Mil)
$0
$6
10%
Enterprise Value (Q1) (Mil)
$4,707
$331
62%
Valuation
RGC
Industry Median
Percentile (All Stocks)
P/B
139.33
2.08
100%
P/E
na
20.9
na
Dividend Yield
na
0.0%
na
PEG (5yr hist)
na
1.1
na
Ratios
RGC
Industry Median
Percentile (All Stocks)
Gross Margin
na
69.5%
na
Net Margin
na
3.6%
na
ROA
(114.2%)
(23.8%)
4%
ROE
(128.5%)
(24.2%)
7%
Liabilities to Assets
9.4%
31.6%
5%
F-Score
3
3
18%
Regencell Bioscience Holdings Limited did not pass any screens on 11/20/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors